Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: A double-blind, placebo-controlled trial

Annals of Internal Medicine

Volumn 121, Issue 11, 1994, Pages 833-841

  Morgan, Sarah L ^a   Baggott, Joseph E ^a   Vaughn, William H ^a   Austin, Janet S ^a   Veitch, Tonya A ^a   Lee, Jeannette Y ^a   Koopman, William J ^a   Krumdieck, Carlos L ^a   Alarcón, Graciela S ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; METHOTREXATE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHEUMATOID ARTHRITIS; STOMATITIS;

ADULT; AGED; ARTHRITIS, RHEUMATOID; DIET; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ERYTHROCYTES; FEMALE; FOLIC ACID; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PATIENT DROPOUTS; TREATMENT OUTCOME; VITAMIN B 12;

EID: 0028593942     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-121-11-199412010-00002     Document Type: Article

References (68)

1. Hanno R, Gruber GG, Owen LG, Callen JP. Methotrexate in psoriasis. A brief review of indications, usage, and complications of methotrexate therapy. J Am Acad Dermatol. 1980;2:171-4.
2. Mullarkey MF, Blumenstein BA, Andrade WP, Bailey GA, Olason I, Wetzel CE. Methotrexate in the treatment of corticosteroid-dependent asthma. A double-blind crossover study. N Engl J Med. 1988;318:603-7.
3. Metzger AL, Bohan A, Goldberg LS, Bluestone R, Pearson CM. Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann Intern Med. 1974;81:182-9.
4. Owen ET, Cohen ML. Methotrexate in Reiter's disease. Ann Rheum Dis. 1979;38:48-50.
5. Huffman GS, Leavitt RY, Kerr GS, Fauci AS. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum. 1992;35:1322-9.
6. Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histological remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989;110:353-6.
7. Williams HJ, Willkens RF, Samuelson CO Jr, Alarcón GS, Guttadauria M, Yarbobo C, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum. 1985;28:721-30.
8. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985;312:818-22.
9. Andersen PA, West SG, O'Dell JR, Via CS, Claypool RG, Kotzin BL. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med. 1985;103:489-96.
10. Thompson RN, Watts C, Edelman J, Esdaile J, Russell AS. A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Rheumatol. 1984;11:760-3.
11. Weinblatt ME, Weissman BN, Holdsworth DE, Fraser PA, Maier AL, Falchuk KR, et al. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Arthritis Rheum. 1992;35:129-37.
12. Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum. 1991;35:138-45.
13. Furst DE, Koehnke R, Burmeister LF, Kohler J, Cargill I. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol. 1989;16:313-20.
14. Alarcón GS, Tracy IC, Blackburn WD Jr. Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum. 1989;32:671-6.
15. Gispen JG, Alarcón GS, Johnson JJ, Acton RT, Barger BO, Koopman WJ. Toxicity to methotrexate in rheumatoid arthritis. J Rheumatol. 1987;14:74-9.
16. Wolfe F, Cathey MA. The effect of age on methotrexate efficacy and toxicity. J Rheumatol. 1991;18:973-7.
17. Furst DE, Erikson N, Clute L, Koehnke R, Burmeister LF, Kohler JA. Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis. J Rheumatol. 1990;17:1628-35.
18. Antonelli MA, Moreland LW, Brick JE. Herpes Zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. Am J Med. 1991;90:295-8.
19. MacKinnon SK, Starkebaum G, Willkens RF. Pancytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis. Semin Arthritis Rheum. 1985;15:119-26.
20. Cannon GW, Ward JR, Clegg DO, Samuelson CO Jr, Abbott TM. Acute lung disease associated with low-dose pulse methotrexate therapy in patients with rheumatoid arthritis. Arthritis Rheum. 1983;26:1269-74.
21. Hargreaves MR, Mowat AG, Benson MK. Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: report of five cases and review of published reports. Thorax. 1992;47:628-33.
22. Walker AM, Funch D, Dreyer NA, Tolman KG, Kremer JM, Alarcón GS, et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum. 1993;36:329-35.
23. Jackson RC. Biological effects of folic acid antagonists with antineoplastic activity. Pharmacol Ther. 1984;25:61-82.
24. Omer A, Mowat AG. Nature of anemia in rheumatoid arthritis. IX. Folate metabolism in patients with rheumatoid arthritis. Ann Rheum Dis. 1968;27:414-24.
25. Morgan SL, Baggott JE, Altz-Smith M. Folate status of rheumatoid arthritis patients receiving long term, low-dose methotrexate therapy. Arthritis Rheum. 1987;30:1348-56.
26. Hine RJ, Alarcón GS, Koopman WJ, Morgan SL, Baggott JE, Clegg DO, et al. Serum folate (FA) levels of rheumatoid arthritis (RA) patients treated with methotrexate (MTX) or other disease-modifying antirheumatic drugs (DMARDs) [Abstract]. Arthritis Rheum. 1990;33: S60.
27. Wilke WS, Krall PL. Resistant rheumatoid arthritis. What to do when conservative therapy doesn't work. Postgrad Med. 1984;75:69-77.
28. Mackenzie AH. Hepatotoxicity of prolonged methotrexate therapy for rheumatoid arthritis. Cleve Clin Q. 1985;52:129-35.
29. Morgan SL, Baggott JE, Vaughn WH, Young PK, Austin JV, Krumdieck CL, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 1990;33:9-18.
30. Stewart KA, Mackenzie AH, Clough JD, Wilke WS. Folate supplementation in methotrexate-treated rheumatoid arthritis patients. Semin Arthritis Rheum. 1991;20:332-8.
31. Joyce DA, Will RK, Hoffman DM, Laing B, Blackbourn SJ. Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann Rheum Dis. 1991;50:913-4.
32. Tishler M, Caspi D, Fishel B, Yaron M. The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients. Arthritis Rheum. 1988;31:906-8.
33. Hanrahan PS, Russell AS. Concurrent use of folinic acid and methotrexate in rheumatoid arthritis. J Rheumatol. 1988;15:1078-80.
34. Buckley LM, Vacek PM, Cooper SM. Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol. 1990;17:1158-61.
35. Shiroky JB, Neville C, Esdaile JM, Choquette D, Zummer M, Hazeltine M, et al. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 1993;36:795-803.
36. Weinblatt ME, Maier AL, Coblyn JS. Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: An 8 week randomized placebo controlled trial. J Rheumatol. 1993;20:950-2.
37. Stenger AA, Houtman PM, Bruyn GA. Does folate supplementation make sense in patients with rheumatoid arthritis treated with methotrexate? Ann Rheum Dis. 1992;51:1019-20.
38. Morgan SL, Baggott JE, Koopman WJ, Krumdieck CL, Alarcón GS. Folate supplementation and methotrexate [Letter]. Ann Rheum Dis. 1993;52:315-6.
39. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.
40. Pocock SJ, Simon R. Sequential treatment assignment with balancing of prognostic factors in the controlled clinical trial. Biometrics. 1975; 31:103-15.
41. Schakel SF, Sievert YA, Buzzard IM. Sources of data for developing and maintaining a nutrient database. J Am Diet Assoc. 1988;88:1268-71.
42. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Kummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum. 1983;26:1346-53.
43. Tamura T. Microbiological assay of folates. In: Picciano MF, Stokstad EL, Gregory JF, eds. Folic Acid Metabolism in Health and Disease. New York: Wiley-Liss; 1990:121-37.
44. Home DW, Patterson D. Lactobacillus casei microbiological assay of folic acid derivatives in 96-well microtiter plates. Clin Chem. 1988;34: 2357-9.
45. Stacewicz-Sapuntzakis M, Bowen PE, Kikendall JW, Burgess M. Simultaneous determination of serum retinol and various carotenoids: their distribution in middle-aged men and women. Journal of Micronutrient Analysis. 1987;3:27-45.
46. 12 level using radioisotope dilution and coated charcoal. Blood. 1965;26:202-14.
47. Omaye ST, Schaus EE, Kutnink MA, Hawkes WC. Measurement of tamin C in blood components by high-performance liquid chromatography. Implication in assessing vitamin C status. Ann N Y Acad Sci. 1987;498:398-401.
48. Bayoumi RA, Rosalki SB. Evaluation of methods of coenzyme activation of erythrocyte enzymes for detection of deficiency of vitamins B1, B2, and B6. Clin Chem. 1976;22:327-35.
49. Waring PP, Fisher D, McDonnell J, McGown EL, Sauberlich HE. A continuous-flow (AutoAnalyzer II) procedure for measuring erythrocyte transketolase activity. Clin Chem. 1982;28:2206-13.
50. Skala JH, Gretz D, Waring PP. An automated continuous-flow procedure for simultaneous measurement of erythrocyte alanine and aspartate aminotransferase activities. Nutrition Research. 1987;7:731-41.
51. Baker H, Frank O. Vitamin A and carotenes. In: Clinical Vitaminology. New York: Interscience Publishers: 1968.
52. Sharp JT, Young DY, Bluhm GB, Brook A, Brower AC, Corbett M, et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum. 1985;28:1326-35.
53. Weinblatt ME, Kaplan H, Germain BF, Merriman RC, Solomon SD, Wall B, et al. Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six-week, double-blind trial. Arthritis Rheum. 1990;33:330-8.
54. Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York: Academic Press; 1977.
55. Borenstein M, Cohen J. Statistical Power Analysis: A Computer Program. Hilldale, New Jersey: Lawerence Erlbaum Associates: 1988.
56. Subar AF, Block G, James LD. Folate intake and food sources in the US population. Am J Clin Nutr. 1989;50:508-16.
57. Morgan SL, Hine RJ, Vaughn WH, Brown A. Dietary intake and circulating vitamin levels of rheumatoid arthritis patients treated with methotrexate. Arthritis Care Res. 1993;6:4-10.
58. Kremer JM, Alarcón GS, Lightfoot RW Jr, Willkens RF, Furst DE, lliams HJ, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum. 1994;3:316-28.
59. Butterworth CE Jr, Tamura T. Folic acid safety and toxicity: a brief review. Am J Clin Nutr. 1989;50:353-8.
60. Weinblatt ME, Fraser P. Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. Arthritis Rheum. 1989;32:1592-6.
61. Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol. 1993;28:466-9.
62. Furst DE. Clinical pharmacology of very low dose methotrexate for use in rheumatoid arthritis. J Rheumatol. 1985;12:11-4.
63. Sinnett MJ, Groff GD, Raddatz DA, Franck WA, Bertino JS Jr. Methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol. 1989;16:745-8.
64. Edelman J, Biggs DF, Jamali F, Russell AS. Low-dose methotrexate kinetics in arthritis. Clin Pharmacol Ther. 1984;35:382-6.
65. Laffourgue P, Monjanel-Mouterde S, Durand A, Catalin J, Acquavia PC. Is there an interaction between low doses of corticosteroids and methotrexate in patients with rheumatoid arthritis? A pharmacokinetic study in 33 patients. J Rheumatol. 1993;20:263-7
66. Centers for Disease Control and Prevention. Recommendation for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Morb Mortal Wkly Rep. 1992;41:1-7.
67. Nightingale SL. Proposals for folic acid fortification and labeling of certain foods to reduce risk of neural tube defects. JAMA. 1993;270:2283.
68. Baggott JE, Morgan SL, Ha TS, Alarcón GS, Koopman WJ, Krumdieck CL. Antifolates in rheumatoid arthritis: a hypothetical mechanism of action. Clin Exp Rheumatol. 1993;11:5101-5.